menu
    • menu
    [{"orgOrder":0,"company":"Trobix Bio","sponsor":"Chartered Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Series A Financing","leadProduct":"TBX201","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Trobix Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trobix Bio \/ Chartered Group","highestDevelopmentStatusID":"4","companyTruncated":"Trobix Bio \/ Chartered Group"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio Ltd \/ OPKO Health"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EnteraBio Ltd

                            Israel arrow
                            Global ChemShow
                            Not Confirmed

                            EnteraBio Ltd

                            Israel arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : OPKO Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Entera Bio Reports Data for Oral GLP-2 Peptide Tablet in Short Bowel Syndrome

                            Details : Entera Bio & Opko Health are developing the first GLP-2 peptide tablet alternative for short bowel syndrome and mucosal inflammation disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 20, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : OPKO Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Trobix Bio

                            Israel arrow
                            Global ChemShow
                            Not Confirmed

                            Trobix Bio

                            Israel arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TBX201

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Chartered Group

                            Deal Size : $3.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics

                            Details : The proceeds are being utilized to advance the development of Trobix's cutting-edge proprietary platform technology and to advance Precision Microbiome Oncology Therapeutics including TBX201, an oral capsule designed to alter the gut microbiome.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : TBX201

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Chartered Group

                            Deal Size : $3.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BiomX

                            Israel arrow
                            Global ChemShow
                            Not Confirmed

                            BiomX

                            Israel arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BX002

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the I...

                            Details : The poster presentation details a phage therapy panel, comprised of phage directed against Klebsiella pneumoniae, showing a broad target host range and the potential to address carbapenem-resistant and extended spectrum beta-lactamase (ESBL)-producing ba...

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 21, 2020

                            Lead Product(s) : BX002

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.